In the past week, NVRO stock has gone down by -3.09%, with a monthly gain of 13.62% and a quarterly plunge of -11.15%. The volatility ratio for the week is 7.38%, and the volatility levels for the last 30 days are 6.71% for Nevro Corp The simple moving average for the last 20 days is 3.03% for NVRO stock, with a simple moving average of -45.62% for the last 200 days.
Is It Worth Investing in Nevro Corp (NYSE: NVRO) Right Now?
The 36-month beta value for NVRO is also noteworthy at 0.90. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NVRO is 35.17M, and at present, short sellers hold a 8.90% of that float. The average trading volume of NVRO on November 08, 2024 was 616.88K shares.
NVRO) stock’s latest price update
The stock price of Nevro Corp (NYSE: NVRO) has plunged by -7.61 when compared to previous closing price of 5.78, but the company has seen a -3.09% decline in its stock price over the last five trading sessions. prnewswire.com reported 2024-10-29 that Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic Neuropathy and Type 2 Diabetes REDWOOD CITY, Calif., Oct. 29, 2024 /PRNewswire/ — Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in the Journal of Pain Research demonstrating significant, durable pain relief and long-term and clinically meaningful reductions in hemoglobin A1c (HbA1c) and weight in study participants with painful diabetic neuropathy (PDN) and Type 2 diabetes who received 10 kHz high-frequency spinal cord stimulation (SCS) therapy.1 Globally, the number of people with diabetes has quadrupled in the last two decades2, and PDN impacts up to 25% of all people with diabetes.3 PDN can have significant impacts on the quality of life for people living with this condition, with symptoms like numbness, tingling/paresthesia, loss of protective sensation, impaired balance, and reduced response to sensory stimuli.4 Patients typically manage PDN with oral pain medications, but the efficacy of these medications is relatively low and can result in intolerable side effects.5 As a result, people with PDN suffer from significantly reduced health-related quality of life (HRQoL), impaired functionality and other comorbidities like sleep disorders, depression, and anxiety.6 The analysis evaluated 144 patients with Type 2 diabetes and refractory PDN who received 10 kHz SCS therapy during the SENZA-PDN randomized controlled trial (RCT), the largest RCT to evaluate SCS to treat PDN.
Analysts’ Opinion of NVRO
Wells Fargo gave a rating of “Underweight” to NVRO, setting the target price at $5.50 in the report published on August 07th of the current year.
NVRO Trading at 1.15% from the 50-Day Moving Average
After a stumble in the market that brought NVRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.41% of loss for the given period.
Volatility was left at 6.71%, however, over the last 30 days, the volatility rate increased by 7.38%, as shares surge +15.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.29% lower at present.
During the last 5 trading sessions, NVRO fell by -3.09%, which changed the moving average for the period of 200-days by -70.77% in comparison to the 20-day moving average, which settled at $5.18. In addition, Nevro Corp saw -75.19% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NVRO
Current profitability levels for the company are sitting at:
- -0.22 for the present operating margin
- 0.66 for the gross margin
The net margin for Nevro Corp stands at -0.18. The total capital return value is set at -0.19. Equity return is now at value -27.22, with -13.21 for asset returns.
Based on Nevro Corp (NVRO), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at -0.28. The debt to equity ratio resting at 0.8. The interest coverage ratio of the stock is -5.2.
Currently, EBITDA for the company is -87.77 million with net debt to EBITDA at -2.19. When we switch over and look at the enterprise to sales, we see a ratio of 0.86. The receivables turnover for the company is 5.74for trailing twelve months and the total asset turnover is 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.77.
Conclusion
In summary, Nevro Corp (NVRO) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
